KPRX: SEC Form 8-K filed by Kiora Pharmaceuticals Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for KPRX
Across the 3 sessions after earlier KPRX headlines, the stock closed higher 1 times and lower 2 times, with a median move of 1.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | KPRX | SPY |
|---|---|---|---|
| Jul 2, 2026 | Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium | -1.1% | -0.1% |
| Jun 18, 2026 | Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model | -1.6% | +0.8% |
| Oct 30, 2025 | Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders | +0.8% | -1.1% |
Quantisnow market dataNASDAQ
KPRX
Kiora Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for KPRX
Full KPRX profile on Quantisnow Follow KPRX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time